{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:03:01Z","timestamp":1782889381288,"version":"3.54.5"},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Gene therapy with hematopoietic stem cells (HSC) is an attractive therapeutic strategy for several forms of primary immunodeficiencies. Current approaches are based on ex vivo gene transfer of the therapeutic gene into autologous HSC by vector-mediated gene transfer. In the past decade, substantial progress has been achieved in the treatment of severe combined immundeficiencies (SCID)-X1, adenosine deaminase (ADA)-deficient SCID, and chronic granulomatous disease (CGD). Results of the SCID gene therapy trials have shown long-term restoration of immune competence and clinical benefit in over 30 patients. The inclusion of reduced-dose conditioning in the ADA-SCID has allowed the engraftment of multipotent gene-corrected HSC at substantial level. In the CGD trial significant engraftment and transgene expression were observed, but the therapeutic effect was transient. The occurrence of adverse events related to insertional mutagenesis in the SCID-X1 and CGD trial has highlighted the limitations of current retroviral vector technology. For future applications the risk-benefit evaluation should include the type of vector employed, the disease background and the nature of the transgene. The use of self-inactivating lentiviral vectors will provide significant advantages in terms of natural gene regulation and reduction in the potential for adverse mutagenic events. Following recent advances in preclinical studies, lentiviral vectors are now being translated into new clinical approaches, such as Wiskott-Aldrich Syndrome.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.682","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"682-689","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Ten years of gene therapy for primary immune deficiencies"],"prefix":"10.1182","volume":"2009","author":[{"given":"Alessandro","family":"Aiuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Roncarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702574116400_R1","doi-asserted-by":"crossref","unstructured":"Geha RS, Notarangelo LD, Casanova JL, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol. 2007;120:776\u2013794.","DOI":"10.1016\/j.jaci.2007.08.053"},{"key":"2019111702574116400_R2","doi-asserted-by":"crossref","unstructured":"Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: Long-term outcome of HSCT in SCID. Blood. 2009;113:4114\u20134124.","DOI":"10.1182\/blood-2008-09-177923"},{"key":"2019111702574116400_R3","doi-asserted-by":"crossref","unstructured":"Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968\u201399. Lancet. 2003;361:553\u2013560.","DOI":"10.1016\/S0140-6736(03)12513-5"},{"key":"2019111702574116400_R4","doi-asserted-by":"crossref","unstructured":"Kohn DB. Gene therapy for childhood immunological diseases. Bone Marrow Transplant. 2008;41:199\u2013205.","DOI":"10.1038\/sj.bmt.1705895"},{"key":"2019111702574116400_R5","doi-asserted-by":"crossref","unstructured":"Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet. 2008;371:2044\u20132047.","DOI":"10.1016\/S0140-6736(08)60874-0"},{"key":"2019111702574116400_R6","doi-asserted-by":"crossref","unstructured":"Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol. 2007;14:337\u2013342.","DOI":"10.1097\/MOH.0b013e3281900f01"},{"key":"2019111702574116400_R7","doi-asserted-by":"crossref","unstructured":"Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270:475\u2013480.","DOI":"10.1126\/science.270.5235.475"},{"key":"2019111702574116400_R8","doi-asserted-by":"crossref","unstructured":"Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science. 1995;270:470\u2013475.","DOI":"10.1126\/science.270.5235.470"},{"key":"2019111702574116400_R9","doi-asserted-by":"crossref","unstructured":"Davis BR, Candotti F. Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. Immunol Res. 2009;44:127\u2013131.","DOI":"10.1007\/s12026-008-8091-4"},{"key":"2019111702574116400_R10","doi-asserted-by":"crossref","unstructured":"Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410\u20132413.","DOI":"10.1126\/science.1070104"},{"key":"2019111702574116400_R11","doi-asserted-by":"crossref","unstructured":"Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield RS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009 Jul 28. [Epub ahead of print.]","DOI":"10.1182\/blood-2009-06-189209"},{"key":"2019111702574116400_R12","doi-asserted-by":"crossref","unstructured":"Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998;4:775\u2013780.","DOI":"10.1038\/nm0798-775"},{"key":"2019111702574116400_R13","doi-asserted-by":"crossref","unstructured":"Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8:423\u2013425.","DOI":"10.1038\/nm0502-423"},{"key":"2019111702574116400_R14","doi-asserted-by":"crossref","unstructured":"Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360:447\u2013458.","DOI":"10.1056\/NEJMoa0805817"},{"key":"2019111702574116400_R15","doi-asserted-by":"crossref","unstructured":"Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117:2233\u20132240.","DOI":"10.1172\/JCI31666"},{"key":"2019111702574116400_R16","doi-asserted-by":"crossref","unstructured":"Cassani B, Mirolo M, Cattaneo F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood. 2008;111:4209\u20134219.","DOI":"10.1182\/blood-2007-05-092429"},{"key":"2019111702574116400_R17","doi-asserted-by":"crossref","unstructured":"Shaw K, Sokolic R, Choi C, et al. Immune reconstitution after gene therapy for adenosine deaminase deficient severe combined immune deficiency (ADA-SCID) [abstract]. Mol Ther. 2009;17:S138.","DOI":"10.1016\/S1525-0016(16)38713-5"},{"key":"2019111702574116400_R18","doi-asserted-by":"crossref","unstructured":"Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood. 2007;109:503\u2013506.","DOI":"10.1182\/blood-2006-06-031476"},{"key":"2019111702574116400_R19","doi-asserted-by":"crossref","unstructured":"Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14:505\u2013513.","DOI":"10.1016\/j.ymthe.2006.06.007"},{"key":"2019111702574116400_R20","doi-asserted-by":"crossref","unstructured":"Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood. 2006;108:2979\u20132988.","DOI":"10.1182\/blood-2006-05-023507"},{"key":"2019111702574116400_R21","doi-asserted-by":"crossref","unstructured":"Carbonaro DA, Jin X, Cotoi D, et al. Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunological reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion. Blood. 2008;111:5745\u20135754.","DOI":"10.1182\/blood-2007-08-103663"},{"key":"2019111702574116400_R22","doi-asserted-by":"crossref","unstructured":"Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185\u20131193.","DOI":"10.1056\/NEJMoa012616"},{"key":"2019111702574116400_R23","doi-asserted-by":"crossref","unstructured":"Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181\u20132187.","DOI":"10.1016\/S0140-6736(04)17590-9"},{"key":"2019111702574116400_R24","doi-asserted-by":"crossref","unstructured":"Schwarzwaelder K, Howe SJ, Schmidt M, et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest. 2007;117:2241\u20132249.","DOI":"10.1172\/JCI31661"},{"key":"2019111702574116400_R25","doi-asserted-by":"crossref","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132\u20133142.","DOI":"10.1172\/JCI35700"},{"key":"2019111702574116400_R26","doi-asserted-by":"crossref","unstructured":"Chinen J, Davis J, De Ravin SS, et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood. 2007;110:67\u201373.","DOI":"10.1182\/blood-2006-11-058933"},{"key":"2019111702574116400_R27","doi-asserted-by":"crossref","unstructured":"Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood. 2005;105:4255\u20134257.","DOI":"10.1182\/blood-2004-12-4837"},{"key":"2019111702574116400_R28","doi-asserted-by":"crossref","unstructured":"Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255\u2013256.","DOI":"10.1056\/NEJM200301163480314"},{"key":"2019111702574116400_R29","doi-asserted-by":"crossref","unstructured":"Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118:3143\u20133150.","DOI":"10.1172\/JCI35798"},{"key":"2019111702574116400_R30","doi-asserted-by":"crossref","unstructured":"Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140:255\u2013266.","DOI":"10.1111\/j.1365-2141.2007.06880.x"},{"key":"2019111702574116400_R31","doi-asserted-by":"crossref","unstructured":"Kang EM, Malech HL. Advances in treatment for chronic granulomatous disease. Immunol Res. 2009;43:77\u201384.","DOI":"10.1007\/s12026-008-8051-z"},{"key":"2019111702574116400_R32","doi-asserted-by":"crossref","unstructured":"Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997;94:12133\u201312138.","DOI":"10.1073\/pnas.94.22.12133"},{"key":"2019111702574116400_R33","doi-asserted-by":"crossref","unstructured":"Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401\u2013409.","DOI":"10.1038\/nm1393"},{"key":"2019111702574116400_R34","doi-asserted-by":"crossref","unstructured":"Dave UP, Akagi K, Tripathi R, et al. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet. 2009;5:e1000491.","DOI":"10.1371\/journal.pgen.1000491"},{"key":"2019111702574116400_R35","doi-asserted-by":"crossref","unstructured":"Shou Y, Ma Z, Lu T, Sorrentino BP. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A. 2006;103:11730\u201311735.","DOI":"10.1073\/pnas.0603635103"},{"key":"2019111702574116400_R36","doi-asserted-by":"crossref","unstructured":"Scobie L, Hector RD, Grant L, et al. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC Gene Oncogenicity. Mol Ther. 2009;17:1031\u20131038.","DOI":"10.1038\/mt.2009.59"},{"key":"2019111702574116400_R37","doi-asserted-by":"crossref","unstructured":"Thornhill SI, Schambach A, Howe SJ, et al. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther. 2008;16:590\u2013598.","DOI":"10.1038\/sj.mt.6300393"},{"key":"2019111702574116400_R38","doi-asserted-by":"crossref","unstructured":"Zhang F, Thornhill SI, Howe SJ, et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood. 2007;110:1448\u20131457.","DOI":"10.1182\/blood-2006-12-060814"},{"key":"2019111702574116400_R39","doi-asserted-by":"crossref","unstructured":"Naumann N, De Ravin SS, Choi U, et al. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD\/SCID mouse xenograft. Gene Ther. 2007;14:1513\u20131524.","DOI":"10.1038\/sj.gt.3303010"},{"key":"2019111702574116400_R40","doi-asserted-by":"crossref","unstructured":"Bosticardo M, Marangoni F, Aiuti A, Villa A, Roncarolo MG. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113:6288\u20136295.","DOI":"10.1182\/blood-2008-12-115253"},{"key":"2019111702574116400_R41","doi-asserted-by":"crossref","unstructured":"Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97:1598\u20131603.","DOI":"10.1182\/blood.V97.6.1598"},{"key":"2019111702574116400_R42","doi-asserted-by":"crossref","unstructured":"Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111:439\u2013445.","DOI":"10.1182\/blood-2007-03-076679"},{"key":"2019111702574116400_R43","doi-asserted-by":"crossref","unstructured":"Wada T, Jagadeesh GJ, Nelson DL, Candotti F. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. Hum Gene Ther. 2002;13:1039\u20131046.","DOI":"10.1089\/104303402753812449"},{"key":"2019111702574116400_R44","doi-asserted-by":"crossref","unstructured":"Klein C, Nguyen D, Liu CH, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood. 2003;101:2159\u20132166.","DOI":"10.1182\/blood-2002-05-1423"},{"key":"2019111702574116400_R45","doi-asserted-by":"crossref","unstructured":"Strom TS, Turner SJ, Andreansky S, et al. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood. 2003;102:3108\u20133116.","DOI":"10.1182\/blood-2002-11-3489"},{"key":"2019111702574116400_R46","unstructured":"Boztug K, Dewey RA, Klein C. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006;8:390\u2013395."},{"key":"2019111702574116400_R47","doi-asserted-by":"crossref","unstructured":"Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119:964\u2013975.","DOI":"10.1172\/JCI37630"},{"key":"2019111702574116400_R48","doi-asserted-by":"crossref","unstructured":"Galy A, Roncarolo MG, Thrasher AJ. Development of lentiviral gene therapy for Wiskott Aldrich syndrome. Expert Opin Biol Ther. 2008;8:181\u2013190.","DOI":"10.1517\/14712598.8.2.181"},{"key":"2019111702574116400_R49","doi-asserted-by":"crossref","unstructured":"Dupre L, Trifari S, Follenzi A, et al. Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. Mol Ther. 2004;10:903\u2013915.","DOI":"10.1016\/j.ymthe.2004.08.008"},{"key":"2019111702574116400_R50","doi-asserted-by":"crossref","unstructured":"Charrier S, Dupre L, Scaramuzza S, et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 2007;14:415\u2013428.","DOI":"10.1038\/sj.gt.3302863"},{"key":"2019111702574116400_R51","doi-asserted-by":"crossref","unstructured":"Marangoni F, Bosticardo M, Charrier S, et al. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models. Mol Ther. 2009;17:1073\u20131082.","DOI":"10.1038\/mt.2009.31"},{"key":"2019111702574116400_R52","doi-asserted-by":"crossref","unstructured":"Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 2005;435:646\u2013651.","DOI":"10.1038\/nature03556"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/682\/645606\/682_689ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/682\/645606\/682_689ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:58:06Z","timestamp":1573977486000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/682\/19867\/Ten-years-of-gene-therapy-for-primary-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.682","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}